Our take
ROSA ONE Brain guides instruments for SEEG, deep brain stimulation, stereotactic biopsy, and ventricular and transnasal endoscopy. Zimmer Biomet cites a study in which robot-assisted SEEG cases were 3 hours and 42 minutes faster on average than frame-based ones.1
It suits hospitals in the United States and Europe running epilepsy and functional neurosurgery programs. Prices are not published.1,3
Scores by criterion
Pricing transparency, 2.5: Zimmer Biomet publishes no prices and directs buyers to its sales representatives.1
Product maturity, 8.5: ROSA ONE Brain was built for stereotactic neurosurgery, with a six-axis arm and force torque sensing, and the current application was cleared by the FDA in May 2022.1,2
Deployment evidence, 8.0: Hospital systems such as RWJBarnabas Health offer ROSA brain surgery for epilepsy, Parkinson's disease, and brain tumors.3
Company durability, 9.5: Zimmer Biomet reported net sales of 8.23 billion dollars in 2025.4
Ease of integration, 7.5: It offers several registration and head-fixation options, including laser facial scanning, and a separate planning station for planning days before surgery.1
Each criterion is defined on our methodology page.
Who uses ROSA ONE Brain and what it's for
The buyer is a hospital neurosurgery program that does SEEG, deep brain stimulation, and other multi-trajectory procedures.1,3
ROSA ONE Brain
The arm stays rigid once a trajectory is set and does not need moving during bilateral cases, and the software builds a 3D map of the brain for the plan.1,3
On November 6, 2026 Zimmer Biomet introduced Surgeon-Guided Autonomy, a framework for linking planning, surgery and recovery data in one loop it calls Predict, Perform, Recover, while the surgeon keeps control. Zimmer Biomet says the framework is a vision and not a product for sale. ROSA Knee with OptimiZe is one of the building blocks it cites alongside the Persona knee, ZB Edge Analytics and the mymobility care platform.14
Pricing
Zimmer Biomet sells ROSA by quote and does not list prices.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where ROSA ONE Brain wins or loses |
|---|---|---|---|---|
| Zimmer Biomet ROSA ONE Brain | Robot built for stereotactic neurosurgery1 | Not published; quote1 | U.S. hospital systems such as RWJBarnabas3 | Neurosurgery robot; quote only; part of Zimmer Biomet |
| Sinovation Medical | SR1, Q300, and X1000 robots plus navigation and laser ablation5 | Not published; about 913,000 yuan average per system in 202512 | More than 400 hospitals in China5 | Sinovation wins on a full brain-surgery range from one supplier. ROSA ONE Brain wins on a robot designed for neurosurgery and U.S. clearance. |
| Remebot | Neurosurgical robots and a semi-active dental implant robot7,13 | Not published7 | More than 400 hospitals in China; 52 neurosurgical robots sold in 20257,8 | Remebot wins on a range that runs from large to smaller hospitals. ROSA ONE Brain wins on a robot designed for neurosurgery and U.S. clearance. |
| Globus Medical ExcelsiusGPS | Rigid arm plus full navigation, CT or fluoroscopy10 | Quote; spec sheet by request10 | 141.0 million dollars of enabling technology sales in 20259 | ExcelsiusGPS wins on one robot for spine and cranial work. ROSA ONE Brain wins on a robot designed for neurosurgery and U.S. clearance. |
| Renishaw neuromate | Stereotactic robot, frame-based or frameless11 | Not published; contact sales11 | Used by teams such as London Health Sciences Centre11 | neuromate wins on frame or frameless stereotaxy. ROSA ONE Brain wins on a robot designed for neurosurgery and U.S. clearance. |
Limits
No published prices.1
Part of a large orthopedics company.4
Product pages are written for health care professionals only.1
What customers say
Where it helps
A robot designed for stereotactic neurosurgery first.1
Where it falls short
Quote-only pricing.1
Company backing
ROSA ONE Brain is made by Zimmer Biomet, which reported net sales of 8.23 billion dollars in 2025, so this page is scoped to its neurosurgery robot.4
Sources
- Zimmer Biomet, ROSA ONE Brain: Robotic Neurosurgery, accessed November 10, 2026
- U.S. FDA, 510(k) K214065, ROSA ONE Brain application, accessed November 10, 2026
- RWJBarnabas Health, ROSA robotic technology for minimally invasive brain surgery, accessed November 10, 2026
- Zimmer Biomet, Fourth Quarter and Full-Year 2025 Financial Results (February 10, 2026), accessed November 10, 2026
- Sinovation, About and company history, accessed November 10, 2026
- Sina Tech, Sinovation files for STAR Market listing, 2025 revenue 189 million yuan (July 3, 2026), accessed November 10, 2026
- China Medical and Surgical Robotics Database, Remebot, accessed November 4, 2026
- MedChina, 2025 China Surgical Robot Sales Annual Report, accessed November 4, 2026
- Globus Medical, fourth quarter and full year 2025 results, SEC Form 8-K exhibit 99.1, accessed November 9, 2026
- Globus Medical, ExcelsiusGPS product page, accessed November 9, 2026
- Renishaw, neuromate stereotactic robot for neurosurgery, accessed November 10, 2026
- Sina Finance, Sinovation prospectus: revenue mix, unit sales and prices (August 31, 2026), accessed November 10, 2026
- China Medical and Surgical Robotics Database, Remebot Dental Robot, accessed November 3, 2026
- Zimmer Biomet, Zimmer Biomet introduces Surgeon-Guided Autonomy, a new category in intelligent surgery, November 6, 2026, accessed November 12, 2026
